Related items

The review of the Cybersecurity Act (CSA 2.0) is an opportunity to build a more coherent, outcome-oriented EU cybersecurity framework. While the proposal recognises fragmentation across the Single Market, further simplification is needed to reduce overlaps and support effective compliance.

A harmonised approach to risk assessment and supervision can strengthen resilience while avoiding duplicative obligations. Certification and supply-chain measures should remain risk-based, objective, technical and aligned with international standards. Structured industry engagement and clear designation thresholds under the ICT Supply Chain Framework and a secure-by-design approach to policymaking will be essential to support cybersecurity and global interoperability. Read more on how CSA 2.0 can strengthen resilience across the Single Market.

From Monday, 27 to Wednesday, 29 April, AmCham EU travelled to Paris, France and the European Parliament in Strasbourg, France for a series of meetings on EU financial services policy developments. The delegation engaged with representatives from French and European financial authorities, Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to share business perspectives on the EU’s financial services agenda. Discussions focused on how to improve Europe’s competitiveness, deepen capital markets and create the right conditions for innovation in digital finance. Members also highlighted the need for more coherent and interoperable rules that reduce complexity while encouraging long-term investment through risk-based regulation.

On Tuesday, 28 to Wednesday, 29 April, AmCham EU travelled to the European Parliament in Strasbourg, France for a series of meetings with policymakers to discuss ongoing EU healthcare policy initiatives. The delegation met with Members of the European Parliament, Accredited Parliamentary Assistants and Group Policy Advisers, to discuss priorities for the EU’s health agenda. This included exchanges on how to strengthen Europe’s life sciences competitiveness and support resilient supply chains. Members also stressed the need for urgent action to simplify overlapping rules and reduce complexity. They underlined that proportionate, risk-based regulation is essential to support innovation. This approach can also help ensure timely patient access to medicines, medical technologies and diagnostics.